Table 2 Overall effects and subgroup analysis for antibiotic resistance pattern in S. aureus recovered from CF patients
Subgroups | Number of studies | Heterogeneity test | Egger’s test | Random model | |||||
|---|---|---|---|---|---|---|---|---|---|
Prevalence (95% CI) (%) | Z | P | Q | P | I2 | T | P | ||
S. aureus | 12 | 40.9% (29.6–53.1) | 1.4 | 0.1 | 185.9 | 0.00 | 94 | 1 | 0.31 |
Subgroup analysis | |||||||||
MRSA | 3 | 18.6% (1.1–82.6) | 0.9 | 0.3 | 146.7 | 0.00 | 98.6 | 0.07 | 0.95 |
Subgroup analysis for antibiotic resistance pattern | |||||||||
Amikacin | 3 | 21.5 ( 12.2–38.3) | 2.3 | 0.00 | 23 | 0.00 | 86 | 1.1 | 0.34 |
Cephazolin | 3 | 12.3 (3.1–22.4) | 3.1 | 0.21 | 44.1 | 0.00 | 73 | 0.1 | 0.22 |
Chloramphenicol | 3 | 9.7 (3.3–32.2) | 21 | 0.00 | 117 | 0.00 | 89 | 2.3 | 0.11 |
Ciprofloxacin | 4 | 54.9 (2.5–98.3) | 0.1 | 0.9 | 33.9 | 0.00 | 97 | 0.12 | 0.33 |
Clindamycin | 4 | 17.9 (12.6–24.9) | 7.1 | 0.00 | 1.2 | 0.00 | 19.8 | 0.12 | 0.14 |
Gentamycin | 4 | 10.8 (6.2–18.3) | 6.7 | 0.00 | 2 | 0.15 | 51.6 | 3.2 | 0.2 |
Linezolid | 5 | 0 (0.1–1.2) | 1 | 0.00 | 2 | 1 | 0.00 | 0.01 | 0.1 |
Vancomycin | 5 | 0 (0.1–1.2) | 1 | 0.00 | 2.1 | 1 | 0.00 | 0.01 | 0.1 |
Trimethoprim-Sulfamethoxazole | 5 | 17 (8.6–30.9) | 3.9 | 0.00 | 5.4 | 0.06 | 63.4 | 5.1 | 0.12 |
Penicillin G | 4 | 94 (70.1–99.1) | 2.8 | 0.005 | 5.7 | 0.016 | 82.6 | 0.1 | 0.21 |
Tetracycline | 4 | 22 (8.6–46) | 2.2 | 0.025 | 6.6 | 0.01 | 84.8 | 1.3 | 0.01 |
Teicoplanin | 3 | 0 (0.1–1.2) | 1 | 0.00 | 2 | 0.001 | 0.00 | 0.01 | 0.1 |
Telithromycin | 3 | 0 (0.1–1.2) | 1 | 0.00 | 2 | 1 | 0.00 | 0.01 | 0.1 |
Cefoxitin | 3 | 100 (99.9–100) | 1 | 0.001 | 3.6 | 0.001 | 89.3 | 0.1 | 0.32 |
Clarithromycin | 3 | 0 (0.1–1.2) | 1 | 0.00 | 2 | 1 | 0.00 | 0.01 | 0.1 |
Oxacillin | 3 | 100 (99.9–100) | 1 | 0.001 | 3.6 | 0.001 | 88.2 | 0.1 | 0.32 |
Tigecycline | 3 | 0 (0.1–1.2) | 1 | 0.00 | 2 | 1 | 0.00 | 0.01 | 0.1 |